natgillin/translations-raw huggingface dataset:
At least one compound as claimed in any one of claims 1 to 3, and/or at least one pharmaceutically acceptable salt thereof, for use in the treatment of cancer as claimed in claim 7, where the cancer is selected from lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer, stomach cancer, kidney cancer, liver cancer, brain cancer, bone cancer, and leukaemia. 
Najmanje jedan spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i/ili najmanje jedna njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu za liječenje raka prema zahtjevu 7, pri čemu je rak odabran od raka pluća, raka glave i vrata, kolorektalnog raka, raka gušterače, raka debelog crijeva, raka dojke, raka jajnika, raka prostate, raka želuca, raka bubrega, raka jetre, raka mozga, raka kosti, te leukemije.
A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: 
Spoj ili njegova farmaceutski prihvatljiva sol, naznačen time, da je spoj odabran iz skupine koju čine:
A pharmaceutical composition comprising an excipient and a therapeutically effective amount of the compound or pharmaceutically acceptable salt of claim 1. 
Farmaceutski pripravak, naznačen time, da sadržava inertni nosač i terapijski učinkovitu količinu spoja ili farmaceutski prihvatljive soli u skladu s patentnim zahtjevom 1.
A composition for use in a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said composition comprising a therapeutically effective amount of the compound or pharmaceutically acceptable salt of claim 1. 
Pripravak za uporabu u postupku liječenja raka mokraćnog mjehura, raka mozga, raka dojke, raka koštane srži, raka grlića maternice, kronične limfocitne leukemije, raka debelog crijeva, raka jednjaka, hepatocelularnog raka, leukemije, folikularnog limfoma, limfne malignosti T-stanica ili B-stanica, melanoma, mijelogene leukemije, mijeloma, oralnog karcinoma, karcinoma jajnika, raka ne-malih stanica pluća, raka prostate, raka malih stanica pluća ili raka slezene kod bolesnika, naznačen time, da sadržava terapijski učinkovitu količinu spoja ili farmaceutski prihvatljive soli u skladu s patentnim zahtjevom 1.
A composition for use in a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said composition comprising a therapeutically effective amount of the compound or pharmaceutically acceptable salt of claim 1 and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. 
Pripravak za uporabu u postupku liječenja raka mokraćnog mjehura, raka mozga, raka dojke, raka koštane srži, raka grlića maternice, kronične limfocitne leukemije, raka debelog crijeva, raka jednjaka, hepatocelularnog raka, leukemije, folikularnog limfoma, limfne malignosti T-stanica ili B-stanica, melanoma, mijelogene leukemije, mijeloma, oralnog karcinoma, karcinoma jajnika, raka ne-malih stanica pluća, raka prostate, raka malih stanica pluća ili raka slezene kod bolesnika, naznačen time, da sadržava terapijski učinkovitu količinu spoja ili farmaceutski prihvatljive soli u skladu s patentnim zahtjevom 1 i terapijski učinkovite količine jednog dodatnog terapijskog sredstva ili više dodatnih terapijskih sredstava.
The proNGF mutant according to claims 1 to 5, wherein the mutant is obtained by recombinant expression in prokaryotic cells, preferably in E. coli. 
proNGF mutant prema zahtjevu 1, naznačen time da se mutant dobiva pomoću rekombinantne ekspresije u prokariotskim stanicama, poželjno pomoću rekombinantne ekspresije u E. coli.
transferring the proNGF mutant into a refolding solution where the denatured proNGF assumes a biologically active conformation; and 
prenošenje proNGF mutanta u otopinu za ponovno preslagivanje gdje denaturirani proNGF podrazumijeva biološki aktivnu konformaciju,
A pharmaceutical composition comprising a crosslinked cation exchange polymer salt and from 10 wt.% to 40 wt.% of a linear sugar based on the total weight of the composition, the crosslinked cation exchange polymer comprising structural units corresponding to Formulae 1 and 2, Formulae 1 and 3, or Formulae 1, 2, and 3, wherein Formula 1, Formula 2, and Formula 3 are represented by the following structures: wherein 
Farmaceutski pripravak naznačen time da sadrži sol umreženog polimera za kationsku izmjenu i od 10 tež.% do 40 tež.% ravnolančanog šećera bazirano na ukupnoj težini pripravka, te umreženi polimer za kationsku izmjenu sadrži strukturne jedinice koje odgovaraju Formulama 1 i 2, Formulama 1 i 3, ili Formulama 1, 2, i 3, pri čemu su Formula 1, Formula 2, i Formula 3 prikazane sa slijedećim strukturama: [image] pri čemu
A pharmaceutical composition comprising a crosslinked cation exchange polymer salt and from 10 wt.% to 40 wt.% of a linear sugar based on the total weight of the composition, the crosslinked cation exchange polymer being a reaction product of a polymerization mixture comprising monomers of either (i) Formulae 11 and 22, (ii) Formulae 11 and 33, or (iii) Formulae 11, 22, and 33, wherein Formula 11, Formula 22, and Formula 33 are represented by the following structures: and wherein 
Farmaceutski pripravak koji sadrži sol umreženog polimera za kationsku izmjenu i od 10 tež.% do 40 tež.% ravnolančanog šećera bazirano na ukupnoj težini pripravka, te je umreženi polimer za kationsku izmjenu reakcijski produkt polimerizacijske mješavine koja sadrži monomere bilo sa (i) Formulama 11 i 22, (ii) Formulama 11 i 33, ili (iii) Formulama 11, 22, i 33, pri čemu su Formula 11, Formula 22, i Formula 33 prikazane slijedećim strukturama: [image] te pri čemu
means for establishing (35d, 35e) a broadcast wireless communication channel (39, 40) for air-to-ground and a ground-to-air communication; 
Sredstva konfigurirana za uspostavu (35d, 35e) radiodifuzijskog bežičnog komunikacijskog kanala (39, 40) za VD mod tipa 2 za zrak-zemlja i zemlja-zrak komunikaciju;
means for establishing (35d, 35e; 35f; 35g), over said broadcast wireless communication channel, a second data communication link (40) with a second aerial vehicle (3); 
Sredstva konfigurirana za uspostavu (35e; 35f; 35g), druge komunikacijske podatkovne veze (40) putem navedenog radiodifuzijskog komunikacijskog kanala s drugim zračnim prometalom (3), druga komunikacijska podatkovna veza je VDL mod 2 digitalna podatkovna veza;
means for broadcasting, over the first and the second communication data link (39, 40), at a first time interval, a first identification message carrying a third code identifying the first airline remote station (4); and 
Sredstva konfigurirana za emitiranje putem prve i druge komunikacijske podatkovne veze (39, 40), u prvom vremenskom intervalu, prva identifikacijska poruka nosi treći kod koji identificira prvu zrakoplovnu daljinsku postaju (4): i
means for broadcasting, over the first and the second communication data link (39, 40), at a second time interval, a second identification message carrying a fourth code identifying the second airline remote station (5). 
Sredstva konfigurirana za emitiranje putem prve i druge komunikacijske podatkovne veze (39, 40), u drugom vremenskom intervalu, druga identifikacijska poruka nosi četvrti kod koji identificira drugu zrakoplovnu daljinsku postaju (5).
means for broadcasting, over the first (39) and the second (40) communication data link, at a first time interval, a first identification message carrying a third code identifying the first communication service provider network (22); and 
Sredstva konfigurirana za emitiranje, putem prve (39) i druge (40) komunikacijske podatkovne veze, u trećem vremenskom intervalu, treća identifikacijska poruka nosi peti kod identificirajući mrežu pružatelja prve komunikacijske usluge (22); i
means for broadcasting, over the third (39) and the fourth (40) communication data link, at a second time interval, a second identification message carrying a fourth code identifying the second communication service provider network (23), the first aerial vehicle (2) being configured for: 
Sredstva konfigurirana za emitiranje, putem prve (39) i druge (40) komunikacijske podatkovne veze, u četvrtom vremenskom intervalu, četvrta identifikacijska poruka nosi šesti kod identificirajući mrežu pružatelja druge komunikacijske usluge (23);
dissolving lercanidipine in an organic solvent to prepare a solution; 
otapanje lerkanidipina u organskom otapalu da bi se dobila otopina;
The method of claim 1, wherein the organic solvent of step (1) is a mixed organic solvent of methylene chloride and t-butyl alcohol, the volume of the mixed organic solvent being 4 to 10 times the volume of the lercanidipine; the organic solvent of step (2) is cyclohexane having a volume 15 to 40 times the volume of the organic solvent of step (1); and the vacuum drying in step (3) takes place at 60 ~ 80 °C for 24 ~ 30 hrs. 
Postupak prema zahtjevu 1, naznačen time da je organsko otapalo prema koraku (1) mješovito organsko otapalo metilen klorida i t-butil alkohola, a volumen mješovitog organskog otapala je 4 do 10 puta volumena lerkanidipina; organsko otapalo iz koraka (2) je cikloheksan koji ima volumen koji je 15 do 40 puta volumena organskog otapala iz koraka (1); te se sušenje iz koraka (3) provodi na 60 ~ 80 °C tijekom 24 ~ 30 sati.
dissolving lercanidipine in at least one organic solvent selected from the group consisting of dimethylsulfoxide, dimethylformamide, 1,4-dioxane and methanol, and cooling to 0 °C; 
otapanje lerkanidipina u najmanje jednom organskom otapalu odabranom iz skupine koju čine dimetilsulfoksid, dimetilformamid, 1,4-dioksan i metanol, te hlađenje na 0°C;
forming precipitates by adding water of 0 ~ 5 °C and stirring; and filtering the precipitates, washing with water, and vacuum drying. 
stvaranje taloga dodavanjem vode 0 ~ 5 °C uz miješanje; te filtriranje taloga, ispiranje s vodom i sušenje u vakuumu.
dissolving lercanidipine in methanol and adding diisopropyl ether to obtain a dilute solution; 
otapanje lerkanidipina u metanolu i dodavanje diizopropil etera da se dobije razrijeđena otopina;
forming precipitates by adding the solution into diisopropyl ether and stirring; and filtering the precipitates, washing with diisopropyl ether and vacuum drying. 
stvaranje taloga dodavanjem otopine u diizopropil eter uz miješanje; i filtriranje taloga, ispiranje sa diizopropil eterom i sušenje u vakuumu.
A polymorph according to claim 1 or claim 2 in that it provides an XRPD pattern substantially in accordance with Figure 1. 
Polimorf u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što daje XRPD uzorak koji u osnovi odgovara Slici 1.
A polymorph according to claim 4 or claim 5 characterised in that it provides an XRPD pattern substantially in accordance with Figure 2. 
Polimorf u skladu s patentnim zahtjevom 4 ili patentnim zahtjevom 5, naznačen time što daje XRPD uzorak koji u osnovi odgovara Slici 2.
A polymorph according to claim 7 or claim 8 characterised in that it provides an XRPD pattern substantially in accordance with Figure 3. 
Polimorf u skladu s patentnim zahtjevom 7 ili patentnim zahtjevom 8, naznačen time što daje XRPD uzorak koji uglavnom odgovara Slici 3.
26.3 3.4 A pharmaceutical composition comprising a polymorph or salt as defined in any one of claims 1 to 3 and one or more pharmaceutically acceptable excipients. 
Farmaceutski pripravak, naznačen time što sadrži polimorf, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, kao i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
Use of a polymorph or salt as defined in any one of claims 1 to 10 in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate Pl3-kinase activity. 
Upotreba polimorfa ili soli u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačena time što su polimorf ili sol namijenjeni proizvodnji medikamenta namijenjenog upotrebi u liječenju poremećaja uzrokovanih neodgovarajućom aktivnošću PI3-kinaze.
The liposome according to claim 4, characterized in that the said liposome has ion gradient formed by a buffer between the internal water phase and the external water phase of the liposome, preferably the internal water phase of the said liposome has higher ion concentration than the external water phase. 
Liposom prema zahtjevu 4, naznačen time što taj liposom ima gradijent iona formiran puferom između unutarnje vodene faze i vanjske vodene faze liposoma, poželjno unutarnja vodena faza tog liposoma ima veću koncentraciju iona od vanjske vodene faze.
The liposome according to any one of the preceding claims, characterized in that the said liposome further comprises a charged phospholipid, wherein the said charged phospholipid is selected from the group consisting of dilauroyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, distearoyl phosphatidyl glycerol, dimyristate phosphatidylglycerol, dioleic acid phosphatidylserine, dioleoyl phosphatidylglycerol, dilauroyl phosphatidic acid, dimyristate phosphatidic acid, distearoyl phosphatidic acid and a mixture thereof, and the weight ratio of the charged phospholipid to the neutral phospholipid is 1:5 ~ 1:100. 
Liposom prema bilo kojem od prethodnih zahtjeva, naznačen time što taj liposom dalje sadrži nabijeni fosfolipid, pri čemu se taj nabijeni fosfolipid izabire iz skupine koja obuhvaća dilauroil fosfatidilglicerol, dipalmitoil fosfatidilglicerol, distearoil fosfatidil glicerol, dimiristat fosfatidilglicerol, fosfatidilserin dioleinske kiseline, dioleoil fosfatidilglicerol, dilauroil fosfatidinske kiseline, dimiristat fosfatidinske kiseline, distearoil fosfatidinske kiseline i njihove mješavine, i težinski omjer nabijenog fosfolipida prema neutralnom fosfolipidu je 1: 5 ~ 1: 100.
dissolving a neutral phospholipid and cholesterol into anhydrous ethanol or a mixed solvent of anhydrous ethanol and tert-butyl alcohol according to the desired formulation, mixing the mixture with a buffer, and then preparing a blank liposome with the desired particle size by using high pressure homogenizer and/or extrusion equipment; 
otapanje neutralnog fosfolipida i kolesterola u bezvodnom etanolu ili miješanom otapalu bezvodnog etanola i tert-butil alkohola ovisno o željenoj formulaciji, miješanje smjese s puferom, i zatim priprema praznog liposoma sa željenom veličinom čestica uporabom opreme homogenizatora s visokim pritiskom i/ili za ekstruziju;
The preparation method according to claim 10, characterized in that after the step 3) of preparation of a drug-loaded liposome, the said method also comprises the following step of: 
Postupak pripreme prema zahtjevu 10, naznačen time što nakon koraka 3) pripreme liposoma napunjenog lijekom, taj postupak također obuhvaća sljedeći korak:
The liposome injection according to claim 13, characterized in that the said injection comprises a stabilizer, wherein the said stabilizer is selected from the group consisting of ethylene diamine tetraacetic acid, ethylene diamine tetraacetic acid disodium, ethylene diamine tetraacetic acid dicalcium and a mixture thereof, preferably ethylene diamine tetraacetic acid disodium; the ratio of the stabilizer added is 0 - 0.5% (w/v), and the minimum is not 0%. 
Injekcija liposoma prema zahtjevu 13, naznačena time što ta injekcija sadrži stabilizator, pri čemu se taj stabilizator izabire iz skupine koja obuhvaća etilen diamin tetraoctenu kiselinu, dinatrij etilen diamin tetraoctene kiseline, dikalcij etilen diamin tetraoctene kiseline i njihove smjese, poželjno dinatrij etilen diamin tetraoctene kiseline; omjer dodanog stabilizatora je 0 ~ 0,5% (tež/vol), i minimum nije 0%.
The liposome injection according to claim 13, characterized in that the said injection comprises an osmotic pressure regulator, wherein the said osmotic pressure regulator is selected from the group consisting of glucose, sucrose, sorbitol, mannitol, sodium chloride, glycerine, histidine and its hydrochloride, glycine and its hydrochloride, lysine, serine, glutamic acid, arginine, valine and a mixture thereof: the ratio of the said osmotic pressure regulator added is 0 ~ 5% (w / v), and the minimum is not 0%. 
Injekcija liposoma prema zahtjevu 13, naznačena time što ta injekcija sadrži regulator osmotskog tlaka, pri čemu se taj regulator osmotskog tlaka izabire iz skupine koja obuhvaća glukozu, saharozu, sorbitol, manitol, natrijev klorid, glicerin, histidin i njegov hidroklorid, glicin i njegov hidroklorid, lizin, serin, glutaminsku kiselinu, arginin, valin i njihove smjese; omjer tog dodanog regulatora osmotskog tlaka je 0 ~ 5% (tež/vol), i minimum nije 0%.
The liposome injection according to claim 13, characterized in that the said injection further comprises an antioxidant, wherein the said antioxidant is selected from the group consisting of a water-soluble antioxidant and an oil-soluble antioxidant: wherein the said oil-soluble antioxidant is selected from the group consisting of a-tocopherol, a-tocopherol succinate, a-tocopherol acetate and a mixture thereof: wherein the said water-soluble antioxidant is selected from the group consisting of ascorbic acid, sodium bisulfite, sodium sulfite, sodium pyrosulfite. L-cysteine and a mixture thereof: the ratio of the antioxidant added is 0 - 0.5% (w/v), and the minimum is not 0%. 
Injekcija liposoma prema zahtjevu 13, naznačena time što ta injekcija dalje sadrži antioksidans, pri čemu se taj antioksidans izabire iz skupine koja obuhvaća u vodi topljiv antioksidans i u ulju topljiv antioksidans; gdje se taj u ulju topljiv antioksidans izabire iz skupine koja obuhvaća a-tokoferol, a-tokoferol sukcinat, a-tokoferol acetat i njihove smjese; gdje se taj u vodi topljiv antioksidans izabire iz skupine koja obuhvaća askorbinsku kiselinu, natrijev bisulfit, natrijev sulfit, natrijev pirosulfit, L-cistein i njihove smjese; omjer dodanog antioksidansa je 0 ~ 0,5% (tež/vol), i minimum nije 0%.
The preparation process according to claim 20. characterized in that the said preparation process further comprises the following steps of: 
Postupak pripreme prema zahtjevu 20, naznačen time što taj postupak pripreme dalje obuhvaća sljedeće korake:
An object of which at least one surface is coated with at least one layer of a paint composition comprising a component A, being a basic binder, and a component B, being an isocyanate prepolymer, wherein the isocyanate prepolymer has an NCO weight percentage of less than or equal to 16 wt.%, and wherein component A has been selected from the group consisting of hydroxyacrylate, polyaspartic ester, polyester polyol, epoxy, silicone epoxide, and one or more combinations hereof and wherein the index, being the ratio between reactive groups of component B and the reactive groups of component A, ranges between 1.5 and 3.0, and characterized in that the layer has a thickness of maximally 150 µm and the layer has a loss of gloss ranging from 0 to 10 measured according to ISO11507:1997 after 1000 hours of irradiation with UV-A light. 
Objekt s barem jednom površinom prekrivenom barem jednim slojem boje koja u sastavu sadrži komponentu A, osnovno vezivo, i komponentu B, prepolimer izocijanata, pri čemu prepolimer izocijanata ima NCO (DUK, dušik, ugljik, kisik) postotak težine niži ili jednak 16 wt.%, te pri čemu je komponenta A odabrana iz skupine koju čine hidroksiakrilat, poliaspartični ester, poliester poliol, epoksi, epoksid silikon, i jedna ili više kombinacija navedenih pri čemu indeks, omjer između reaktivnih grupa komponenti B i reaktivnih grupa komponenti A, iznosi između 1.5 i 3.0, te naznačen time što debljina sloja iznosi maksimalno 150 µm te sloj ima gubitak sjaja u opsegu od 0 do 10 mjereno sukladno ISO11507:1997 nakon 1000 sati iradijacije UV-A svjetlom.
An object according to any one or more of claims 1-3, characterised in that component B of the paint composition is an aromatic isocyanate prepolymer and/or an aliphatic isocyanate prepolymer. 
Objekt sukladno bilo kojem ili više Zahtjeva 1 – 3, naznačen time što je komponenta B sastava boje aromatični prepolimer izocijanata i/ili alifatski prepolimer izocijanata.
An object according to claim 4, characterised in that component B of the paint composition is an aliphatic isocyanate prepolymer. 
Objekt sukladno Zahtjevu 4, naznačen time što je komponenta B sastava boje alifatski prepolimer izocijanata.
An object according to any one of the preceding claims, characterised in that the layer has a flexibility ranging from 1 to 9 mm measured according to ISO1520:1999. 
Objekt sukladno bilo kojem od prethodnih Zahtjeva, naznačen time što sloj ima fleksibilnost u opsegu od 1 do 9 mm mjereno sukladno ISO1520:1999.
Use of a paint composition comprising a component A, being a basic binder and a component B, being an isocyanate prepolymer, wherein the isocyanate prepolymer has an NCO weight percentage of less than or equal to 16 wt.%, and wherein component A has been selected from the group consisting of hydroxyacrylate, polyaspartic ester, polyester polyol, epoxy, silicone epoxide, and one or more combinations hereof and wherein the index, being the ratio between reactive groups of component B and the reactive groups of component A, ranges between 1.5 and 3.0 as a paint or top coat having a thickness of maximally 150 µm and the layer has a loss of gloss ranging from 0 to 10 measured according to ISO11507:1997 after 1000 hours of irradiation with UV-A light. 
Uporaba sastava boje koji sadrži komponentu A, kao osnovno vezivo te komponentu B, kao prepolimer izocijanata, pri čemu prepolimer izocijanata ima NCO (DUK, dušik, ugljik, kisik) postotak težine niži ili jednak 16 wt.%, te pri čemu je komponenta A odabrana iz skupine koju čine hidroksiakrilat, poliaspartični ester, poliester poliol, epoksi, epoksid silikon, i jedna ili više kombinacija navedenih pri čemu indeks, omjer između reaktivnih grupa komponenti B i reaktivnih grupa komponenti A, iznosi između 1.5 i 3.0, te naznačen time što debljina sloja iznosi maksimalno 150 m µm te sloj ima gubitak sjaja u opsegu od 0 do 10 mjereno sukladno ISO11507:1997 nakon 1000 sati iradijacije UV-A svjetlom.
Compounds as claimed in claim 1 for use according to claim 1 in the treatment of cognitive impairment associated with a pharmacological treatment of a disease of claim 1. 
Spojevi kako su prijavljeni u patentnom zahtjevu 1 za upotrebu prema patentnom zahtjevu 1, naznačeni time da su za liječenje kognitivnig poremećaja povezanih s farmakološkim liječenjem bolesti iz patentnog zahtjeva 1.
determining coding units of a hierarchical structure by splitting a maximum coding unit according to split information about whether to divide a coding unit, the split information parsed from a received bitstream (2210); 
određivanje kodirajućih jedinica hijerarhijske strukture razdvajanjem maksimalne kodirajuće jedinice u skladu s informacijom o razdvajanju o tome da li će se podijeliti kodirajuću jedinicu, te je informacija o razdvajanju raščlanjena iz primljenog toka bitova (2210);
each of HX1 and HX2 is independently a monoprotic acid. 
svaki od HX1 i HX2 je neovisno protična kiselina.
The device according to any one of claims 1 to 3, characterized in that said solid core (1) is preferably helically surrounded by a small section solid element (8) to contribute to the integrity of the polymer and antibiotic layer (7) arranged thereon. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je navedena puna jezgra (1) po mogućnosti helikoidalno okružena punim elementom (8) malog presjeka koji doprinosi cjelovitosti polimera i antibiotskog sloja (7) raspoređenog na njemu.